Keito Suto

5PUBLICATIONS
8CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.

|Nov 10, 2025
Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Oct 21, 2024
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama

|Dec 24, 2023
Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.

Masahiro Chiba, Joji Shimono, Keito Suto

|Jan 05, 2021
Extramedullary hematopoiesis of the cranial dura.

Keito Suto, Junichi Sugita, Daigo Hashimoto

Pageof 1

Frequent Collaborators

4 joint publications

Masahiro Chiba

4 joint publications

Takanori Teshima

4 joint publications

Yibin Yang

4 joint publications

Masao Nakagawa